مجموعة واي إنوفيشنز
Group with advisory, venture capital and studio arms working in AI, energy and life sciences, led by CEO Megan Yung. Co-brand of the 2025 Sarat Ventures biotech fund.
Industry: Life sciences venture and advisory | Location: Boston, United States
About مجموعة واي إنوفيشنز
Y Innovations Group describes itself as a holding of several arms working across artificial intelligence, energy and life sciences. Its website lists The Firm, an advisory and consulting arm covering strategic planning, intellectual property strategy, market research, investment analysis, business development and chemistry, manufacturing and controls, quality and regulatory work; Yung Ventures, a venture capital arm making thesis-driven investments in life sciences and the energy transition; The Studios, its innovation studios; and a Yung Family Office. The site cites a focus on deals with more than USD 50 million in upfront payments.
On 31 July 2024 the group announced, in a release datelined Boston, an expansion of the group with Y Innovations Studios, an early-stage venture studio that pairs young companies with operational experts, and Yung Ventures, which provides capital at various stages. The release named Megan Yung as Chief Executive Officer and General Partner and Martijn Fleuren as Chief Investment Officer and General Partner, and called the group science- and technology-first. Private Equity International lists Yung, Fleuren and Ipsita Roymoulik, a partner, in Boston, while describing the firm as a London-based venture conglomerate that combines strategic consulting and startup incubation.
In September 2025 the group was named in the Sarat Ventures Y Innovations Biotech Fund (UK), announced on 10 September 2025 with an expected size of about USD 50 million for early-stage biotechnology companies tied to Saudi Arabia and the wider Middle East and North Africa region. Allocator One was named as anchor, and Yung of Yung Ventures and Dr Huda Alfardus were named as general partners. The release described Y Innovations Group as a life sciences venture conglomerate with diligence capabilities and a record of moving early science towards therapeutics.